Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8716698 | 0.85 | POLB (0.65) | ALDH1A1KDM4EPOLBHTTLIMK2 | |
| SCHEMBL8752511 | 0.83 | POLB (0.63) | ALDH1A1POLBHTTLIMK2MEN1 | |
| SCHEMBL3380247 | 0.83 | POLB (0.68) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL8711266 | 0.82 | POLB (0.78) | ALDH1A1POLBHTTLIMK2MEN1 | |
| SCHEMBL6607377 | 0.80 | GAA (0.62) | ALDH1A1KDM4EPOLBHTTMEN1 | |
| SCHEMBL13816414 | 0.79 | PTGDR2 (1.00) | ALDH1A1KDM4EPTGDR2HTTMEN1 | |
| SCHEMBL7571620 | 0.79 | POLB (0.68) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL789616 | 0.79 | KEAP1 (0.72) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL7572319 | 0.79 | POLB (0.68) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL5458136 | 0.78 | POLB (1.00) | ALDH1A1KDM4EPOLBHTTLIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | ALDH1A1 816/4885KDM4E 1824/4885POLB 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.